Boston, MA -- (ReleaseWire) -- 04/11/2014 -- Global Markets Direct's, 'Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2014', provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)'s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
View Full Report Details and Table of Contents
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Companies Mentioned in this Report: Bristol-Myers Squibb Company, Johnson & Johnson, Sanofi, GlaxoSmithKline plc, Seattle Genetics, Inc., MedImmune, LLC, medac GmbH, Merck & Co., Inc., Gamida Cell Ltd., Bio-Path Holdings, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Astex Pharmaceuticals, Inc., Onyx Pharmaceuticals, Inc., Incyte Corporation, 4SC AG, Immunomedics, Inc., Ariad Pharmaceuticals, Inc., OncoVista Innovative Therapies, Inc., Jazz Pharmaceuticals plc, Portola Pharmaceuticals, Inc., Mundipharma International Limited, MorphoSys AG, Threshold Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., Sareum Holdings plc, SymBio Pharmaceuticals Limited, Oryzon Genomics S.A., Spectrum Pharmaceuticals, Inc., Ambit Biosciences Corporation, Abiogen Pharma S.p.A., ERYtech Pharma, Celator Pharmaceuticals, Inc., Aileron Therapeutics, Inc., TetraLogic Pharmaceuticals, CanBas Co., Ltd., Deciphera Pharmaceuticals, LLC, Onconova Therapeutics, Inc., Effimune SAS, Kainos Medicine, Inc., Polyphor Ltd., Syndax Pharmaceuticals, Inc., Omeros Corporation, SBI Biotech Co., Ltd., Kiadis Pharma B.V., Bellicum Pharmaceuticals, Inc., Sigma-Tau Pharmaceuticals, Inc, Interprotein Corporation, EpiZyme, Inc., NuCana BioMed Limited, Pfenex Inc., Otsuka Holdings Co., Ltd., Bexion Pharmaceuticals, LLC., Karyopharm Therapeutics, Inc., International Biotechnology Center Generium, Rhizen Pharmaceuticals SA, ARA Healthcare Pvt. Ltd., Cantargia AB, Formula Pharmaceuticals, Inc., AbbVie Inc., Amgen Astellas BioPharma K.K.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013
- Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2011 - 2020)
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
- T-Cell Leukemia - Pipeline Review, H1 2014
- Acute Pain - Pipeline Review, H1 2014
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014
- Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014
- Acute Promyelocytic Leukemia - Pipeline Review, H2 2013